Legal cannabis stores linked to fewer opioid deaths in the United States

January 27, 2021

Access to legal cannabis stores is associated with a reduction in opioid related deaths in the United States, particularly those linked to synthetic opioids such as fentanyl, finds a study published by The BMJ today.

Opioids are 'morphine-type' drugs that relieve short-term (acute) pain and pain at the end of life. There is little evidence that they are helpful for long-term (chronic) pain, but they are often prescribed for this reason.

This has led to widespread misuse and a sharp rise in overdose deaths, particularly in the United States. In 2018, there were more than 46,000 fentanyl related deaths, representing over two thirds of all US opioid related deaths that year.

Some studies have suggested that increased access to cannabis stores - legally authorised to sell medical and recreational cannabis - may help to reduce opioid related deaths, but the evidence so far is mixed.

To explore this further, researchers examined relationships between medical and recreational cannabis stores (referred to as dispensaries) and opioid related deaths from 2014 to 2018.

Their findings are based on data for 812 counties within the 23 US states that allowed legal cannabis dispensaries to operate by the end of 2017.

Information on state level cannabis legislation was combined with county level data on licensed dispensaries and opioid related mortality rates.

After controlling for population characteristics and other potentially influential factors, the researchers found that counties with a higher number of active cannabis dispensaries were associated with reduced opioid related mortality rates.

According to this estimate, an increase from one to two dispensaries in a county was associated with an estimated 17% reduction in all opioid related mortality rates.

This association held for both medical and recreational dispensaries and appeared particularly strong for deaths associated with synthetic opioids other than methadone, with an estimated 21% reduction in mortality rates associated with an increase from one to two dispensaries.

An increase from two to three dispensaries was associated with a further 8.5% reduction in all opioid related mortality rates.

This study is the first to examine the association between active cannabis dispensary operations and opioid related mortality rates at the more fine grained county level.

However, the results are observational, so can't establish cause, and the researchers stress that while cannabis is generally thought to be less addictive than opioids, it still carries potential harms and public safety risks should not be ignored.

But they say their findings suggest "a potential association between increased prevalence of medical and recreational cannabis dispensaries and reduced opioid related mortality rates."

And they call for "a greater understanding of the impact of cannabis legalization on opioid misuse and public health outcomes before policy makers can weigh the potential benefits against the harms of promoting cannabis legalization."

In a linked editorial, researchers argue that cannabis liberalization "cannot be regarded as a remedy to the opioid crisis until a robust evidence base is available."

Although some may interpret these findings as evidence supporting cannabis liberalization to address the opioid crisis, they point out that "such conclusions are currently premature without evidence of causality."

Further experimental studies including individual level data of those with use of prescription opioids and illicit opioids "would inform a more nuanced understanding of the substitution between opioids and cannabis," they conclude.
-end-
Peer reviewed? Yes (research); No (linked editorial)
Evidence type: Observational; Opinion
Subjects: Legal cannabis stores

BMJ

Related Cannabis Articles from Brightsurf:

Cannabis to treat gynecological conditions
A significant number of women would consider using cannabis to treat gynecological conditions, primarily gynecological pain.

Cannabis data lacking, but machine learning could help
Everyone's heard of THC and CBD. But many other active compounds in cannabis interact to influence its effects.

Cannabis use for menopause symptom management
CLEVELAND, Ohio (September 28, 2020)--As legislation relaxes regarding cannabis, it is being used to manage numerous chronic health conditions and mood symptoms.

Prescribed CBD could help people quit cannabis
A benchmark clinical trial published today shows that cannabidiol (CBD) could be a safe and effective treatment for problematic cannabis use.

Pregnant women with depression are more than 3 times more likely to use cannabis
Cannabis use is much more common among pregnant women with depression and pregnant women with depression are more than 3 times more likely to use cannabis than those without depression.

Cannabis compound acts as an antibiotic 
Public health agencies worldwide have identified antibiotic resistance of disease-causing bacteria as one of humanity's most critical challenges.

Cannabis use during pregnancy
The large health care system Kaiser Permanente Northern California provides universal screening for prenatal cannabis use in women during pregnancy by self-report and urine toxicology testing.

Questions and answers about cannabis use during pregnancy
A new study shows that women have many medical questions about the use of cannabis both before and during pregnancy, and during the postpartum period while breastfeeding.

Managing cannabis use in breastfeeding women
As more states legalize medicinal and recreational cannabis use and increasingly decriminalize cannabis, the risk to the growth and development of breastfeeding infants whose mothers use cannabis becomes a growing public health concern.

Cannabis edibles present novel health risks
With the recent legalization of cannabis edibles in Canada, physicians and the public must be aware of the novel risks of cannabis edibles, argue authors in a commentary in CMAJ (Canadian Medical Association Journal).

Read More: Cannabis News and Cannabis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.